Have you and your family had your flu shot? It's more important than ever this year! Schedule via MyChart or call for an appointment in SF, the East Bay or San Mateo.

Renata C. Gallagher


Medical geneticist
Biochemical geneticist
Director, Biochemical Genetic Medicine
Medical Director, Metabolism Clinic
Cyclist and water sport enthusiast

Dr. Renata C. Gallagher is a doctor who specializes in genetics. She cares for children and adults with rare disorders that affect important biochemical pathways in the body, including those that help make energy, recycle body components and facilitate communication between nerve cells in the brain. Her expertise includes blood tests given at birth as part of a test series designed to identify children with certain treatable conditions that appear early in life. She helps diagnose and treat patients with these rare disorders, and she designs individualized treatment plans together with a specialized team dedicated to the care of these conditions. She directs the UCSF Biochemical Genetic Medicine Service, and is medical director of the UCSF Metabolism Clinic.

Gallagher's research focuses on improving diagnosis and therapies for the rare conditions she treats. Her primary areas of interest are improving and expanding newborn screening for these conditions, optimizing recognition and treatment of pyridoxine-dependent epilepsy (a treatable cause of early-onset, severe seizures), and clarifying the spectrum of liver disease in urea cycle defects (which interfere with the body's ability to remove certain waste products from the bloodstream).

Gallagher earned her medical degree and a doctorate in biochemistry at UCSF. She completed a residency in pediatrics at the University of Washington, followed by fellowships in medical genetics and clinical biochemical genetics at Stanford University.

A fellow of the American College of Medical Genetics and Genomics, Gallagher belongs to the Society for Inherited Metabolic Disorders, Society for the Study of Inborn Errors of Metabolism and American Society of Human Genetics.

During a break in her education, Gallagher traveled around the world, visiting 27 countries in 10 months. In her free time, she loves cycling, swimming, sailing, kayaking and taking long walks on the beach with her family.

  • Education

    UCSF, PhD, Biochemistry, 1996

    UCSF School of Medicine, 1997

  • Residencies

    University of Washington, Pediatrics, 2001

  • Fellowships

    Stanford University, Medical Genetics, 2004

    Stanford University, Clinical Biochemical Genetics, 2005

  • Board Certifications

    Clinical Biochemical Genetics, American Board of Medical Genetics

    Clinical Genetics, American Board of Medical Genetics

    Pediatrics, American Board of Pediatrics

  • Academic Title


I am inspired by my patients and their families, and by my dedicated colleagues, to be the best possible physician, teacher, researcher and lifelong learner.

Biochemical Genetic Medicine Clinic

Ron Conway Family Gateway Medical Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

Lysosomal Storage Disease Center

Ron Conway Family Gateway Medical Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

My reviews


Overall Experience
38 Reviews
Our doctor was very kind patient and thorough
Explained things in a way that was easy to understand
38 Reviews
Did the doctor pay attention to your concerns
38 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
38 Reviews
Knew the important information about your medical history
38 Reviews
The provider showed respect for what you had to say
64 Reviews
The provider spent enough time with me
12 Reviews
Decorative Caduceus

Longitudinal Study of Urea Cycle Disorders

hyperammonemia, developmental disabilities, long-term renal and hepatic effects, and case-fatality associated with the various forms of UCD


Decorative Caduceus

Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency

The incidence of adverse events (AEs), treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs) for each dosing cohort, assessed by severity and relationship to study product.